Literature DB >> 20571281

Role of Fosinopril and Valsartan on Klotho Gene Expression Induced by Angiotensin II in Rat Renal Tubular Epithelial Cells.

Q Zhou1, S Lin, R Tang, P Veeraragoo, W Peng, R Wu.   

Abstract

BACKGROUND/AIMS: Klotho gene, a new anti-aging gene, is mainly expressed in the kidney tubules. Several studies have found the relationship between klotho and emergence and development of renal diseases. This study set out to explore the role of fosinopril (Fos) and valsartan (Val) on klotho expression induced by angiotensin II (Ang II) in rat renal tubular epithelial cells (NRK-52E).
METHODS: NRK-52E cells were divided into five groups according to the treatment of Ang II, Fos and Val. Transforming growth factor-β1 (TGF-β1), p38, phospho-p38 (p-p38), p53, and Sp1 protein expression were determined by immunohistochemical and Western blotting analysis. Klotho expression was detected by reverse transcription-polymerase chain reaction and Western blotting analysis.
RESULTS: Ang II upregulated TGF-β1, p-p38 and p53 expression, and inhibited Sp1 and klotho expression in NRK-52E cells. After the intervention of Fos and/or Val, TGF-β1, p-p38 and p53 expression were downregulated, Sp1 and klotho expression were upregulated. TGF-β1 and p53, Sp1 and klotho expression exhibited a positive linear correlation, respectively.
CONCLUSION: We conclude that Fos and Val have a protective role in Ang II-induced renal damage, and it may be through mechanism of inhibiting TGF-β1, p-p38 and p53 expression, thus upregulating Sp1 and klotho expression.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571281     DOI: 10.1159/000316703

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  25 in total

Review 1.  A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy.

Authors:  Jing-Fu Bao; Pan-Pan Hu; Qin-Ying She; Aiqing Li
Journal:  J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 10.121

Review 2.  Klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

Review 3.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.

Authors:  Ming Chang Hu; Kazuhiro Shiizaki; Makoto Kuro-o; Orson W Moe
Journal:  Annu Rev Physiol       Date:  2013       Impact factor: 19.318

4.  Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin System.

Authors:  Lili Zhou; Hongyan Mo; Jinhua Miao; Dong Zhou; Roderick J Tan; Fan Fan Hou; Youhua Liu
Journal:  Am J Pathol       Date:  2015-10-24       Impact factor: 4.307

5.  Klotho mitigates cyclosporine A (CsA)-induced epithelial-mesenchymal transition (EMT) and renal fibrosis in rats.

Authors:  Qi-Feng Liu; Jian-Ming Ye; Li-Xia Yu; Xiao-Hong Dong; Jian-Hua Feng; Yan Xiong; Xiao-Xia Gu; Sha-Sha Li
Journal:  Int Urol Nephrol       Date:  2016-10-28       Impact factor: 2.370

Review 6.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease.

Authors:  Martin H de Borst; Marc G Vervloet; Piet M ter Wee; Gerjan Navis
Journal:  J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 10.121

Review 8.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

9.  Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy.

Authors:  Md Abdul Hye Khan; Brian Fish; Geneva Wahl; Amit Sharma; John R Falck; Mahesh P Paudyal; John E Moulder; John D Imig; Eric P Cohen
Journal:  Clin Sci (Lond)       Date:  2016-01-15       Impact factor: 6.124

10.  Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.

Authors:  Zhongyan Liu; Hao Zhou; Xiaoying Chen; Hong Chen; Yi Wang; Ting Wang; Luyan Cai; Yanyan Hong; Hailun Ke; Jing Zheng
Journal:  Int Urol Nephrol       Date:  2019-01-28       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.